Semax (10MG)

Description

Semax is a synthetic heptapeptide analogue of the ACTH(4-7) fragment, with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, extended with a C-terminal Pro-Gly-Pro tripeptide to improve metabolic stability. Developed in Russia, it is supplied as a lyophilized powder for in vitro research applications involving neuropeptide signalling, BDNF pathway biology, and ACTH receptor pharmacology.

Molecular Profile
CAS Number: 80714-61-0
Molecular Weight: 813.94 Da
Sequence: Met-Glu-His-Phe-Pro-Gly-Pro (7 amino acids, ACTH 4-7 Pro-Gly-Pro analogue)
Format: Lyophilized white powder
Storage: -20°C, desiccated
Reconstitution: Sterile bacteriostatic water

Research Context
Semax has been studied extensively in Russian neuropeptide research with increasing representation in international literature. Documented in vitro applications include BDNF and BDNF-TrkB receptor signalling studies, NGF pathway modulation research, serotonin and dopamine receptor interaction assays, and melanocortin receptor (ACTH fragment) pharmacology. It is also used in neuroprotection signalling models and as a reference compound in studies investigating the biological activity of ACTH-derived peptide fragments in neural cell systems.

This compound is available exclusively for in vitro laboratory research and scientific study conducted within Canada. It is not a drug, natural health product, or food product as defined under the Food and Drugs Act (R.S.C., 1985, c. F-27). It is not approved for human consumption, veterinary use, or any diagnostic or therapeutic application. This product has not been evaluated by Health Canada. Researchers are responsible for compliance with all applicable federal, provincial, and local regulations.